Evidence map›Paper›PMID 24332997›Full record

Trial reportJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2014

Iron supplementation does not worsen respiratory health or alter the sputum microbiome in cystic fibrosis.

Alex H Gifford, Diana M Alexandru, Zhigang Li, Dana B Dorman, Lisa A Moulton, Katherine E Price, Thomas H Hampton, Mitchell L Sogin, Jonathan B Zuckerman, H Worth Parker and 2 more

2 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01755455 nacompletednot on this map

Iron Supplementation for the Hypoferremic Anemia of Cystic Fibrosis

TypeinterventionalSponsorDartmouth-Hitchcock Medical CenterRan2011 to 2012Enrolled22ConditionsCystic Fibrosis, Anemia, Iron-DeficiencyArmsFerrous sulfate 325mg, Placebo
NCT02188758 completednot on this map

Do Changes in Serum Hepcidin-25 Concentration Predict Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment Responses?

TypeobservationalSponsorDartmouth-Hitchcock Medical CenterRan2014 to 2018Enrolled20ConditionsCystic FibrosisArmsAdults - CFPE Treatment
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Guideline
  2. Changes in Mineral Micronutrient Status During and After Pulmonary Exacerbation in Adults With Cystic Fibrosis.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2015
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Iron, Hepcidin, and Immunity.Advances in experimental medicine and biology · 2025
    Review
  9. Association between CFTR modulators and changes in iron deficiency markers in cystic fibrosis.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024
    Article
  10. Update on the management of vitamins and minerals in cystic fibrosis.Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2022
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Alex H GiffordPulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, United States. Electronic address: Alex.H.Gifford@hitchcock.org.
Diana M AlexandruDivision of Pulmonary and Critical Care, Maine Medical Center, Portland, ME 04102, United States. Electronic address: ALEXAD1@mmc.org.
Zhigang LiBiostatistics and Epidemiology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, United States. Electronic address: Zhigang.Li@dartmouth.edu.
Dana B DormanPulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, United States. Electronic address: Dana.B.Dorman@hitchcock.org.
Lisa A MoultonPulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, United States. Electronic address: Lisa.A.Moulton@hitchcock.org.
Katherine E PriceMicrobiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, United States. Electronic address: Katherine.E.Price@dartmouth.edu.
Thomas H HamptonMicrobiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, United States. Electronic address: Thomas.H.Hampton@dartmouth.edu.
Mitchell L SoginJosephine Bay Paul Center for Comparative Molecular Biology and Evolution, Marine Biological Laboratory, Woods Hole, MA 02543, United States. Electronic address: sogin@mbl.edu.
Jonathan B ZuckermanDivision of Pulmonary and Critical Care, Maine Medical Center, Portland, ME 04102, United States. Electronic address: jzuckerman@cmamaine.com.
H Worth ParkerPulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, United States. Electronic address: H.Worth.Parker@hitchcock.org.
Bruce A StantonMicrobiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, United States. Electronic address: bas@dartmouth.edu.
George A O'TooleMicrobiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, United States. Electronic address: georgeo@dartmouth.edu.
Dartmouth College · USDartmouth–Hitchcock Medical Center · USMaine Medical Center · USMarine Biological Laboratory · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
THE ROLE OF CAL IN CIF-MEDIATED DEGRADATION OF CFTRP20RR018787 · NCRR · DARTMOUTH COLLEGE · PI STANTON, BRUCE A. · 2003 to 2011
$21.9M
IMMUNOBIOLOGY OF MYELOID AND LYMPHOID CELLST32AI007363 · NIAID · DARTMOUTH COLLEGE · PI Claudia V Jakubzick · 1990 to 2026
$9.5M
TRANSLATIONAL RESEARCH COREP30GM106394 · NIGMS · DARTMOUTH COLLEGE · PI MADDEN, DEAN R · 2013 to 2017
$6.1M
Role of Virulence Factors in Pseudomonas-Host InteractionsR01HL074175 · NHLBI · DARTMOUTH COLLEGE · PI STANTON, BRUCE A. · 2003 to 2018
$5.0M
Mechanism of Cif Virulence: A Bacterial Strategy to Subvert Host-Cell DefensesR01AI091699 · NIAID · DARTMOUTH COLLEGE · PI MADDEN, DEAN R, O'TOOLE, GEORGE A. · 2012 to 2016
$2.3M
Cellular and Molecular Mechanisms of Lung DiseaseP20GM103413 · NIGMS · DARTMOUTH COLLEGE · PI STANTON, BRUCE A. · 2012 to 2012
$2.1M
NCI NIH HHS P30 CA023108NCRR NIH HHS P20 RR018787NHLBI NIH HHS L30 HL110115NHLBI NIH HHS R01 HL074175NHLBI NIH HHS R01-HL074175-09NIAID NIH HHS R01 AI091699NIAID NIH HHS T32 AI007363NIGMS NIH HHS 20-GM103413-10NIGMS NIH HHS P20 GM103413NIGMS NIH HHS P30 GM106394
6 · The paper itself

Abstract

backgroundIron supplementation for hypoferremic anemia could potentiate bacterial growth in the cystic fibrosis (CF) lung, but clinical trials testing this hypothesis are lacking.

methodsTwenty-two adults with CF and hypoferremic anemia participated in a randomized, double-blind, placebo-controlled, crossover trial of ferrous sulfate 325mg daily for 6weeks. Iron-related hematologic parameters, anthropometric data, sputum iron, Akron Pulmonary Exacerbation Score (PES), and the sputum microbiome were serially assessed. Fixed-effect models were used to describe how ferrous sulfate affected these variables.

resultsFerrous sulfate increased serum iron by 22.3% and transferrin saturation (TSAT) by 26.8% from baseline (p<0.05) but did not affect hemoglobin, sputum iron, Akron PES, and the sputum microbiome.

conclusionsLow-dose ferrous sulfate improved hypoferremia without correcting anemia after 6weeks. We did not observe significant effects on sputum iron, Akron PES, and the sputum microbiome. Although we did not identify untoward health effects of iron supplementation, a larger blinded randomized controlled trial would be needed to fully demonstrate safety.

Indexed as

AdolescentAdultAnemia, Iron-DeficiencyCross-Over StudiesCystic FibrosisDouble-Blind MethodFemaleFerrous CompoundsHepcidinsHumansMaleMicrobiotaMiddle AgedPlacebosSputumTreatment OutcomeFerrous Compoundsferrous sulfatehepcidin 25, humanHepcidinsPlacebosAnemiaCystic fibrosisHepcidin-25HypoferremiaIronMicrobiome

Identifiers

PMID24332997
PMCPMC3972336
OpenAlexW1966040104

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.